Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00972777 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
A Phase 2 study of Bacterial Conjunctivitis, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 474
- Enrollment target
- 1
- Study location
NCT00972777 is a Phase 2 study of Bacterial Conjunctivitis that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 474 participants, below the 557-participant average among 7 other Bacterial Conjunctivitis trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00972777, a Phase 2 study of Bacterial Conjunctivitis, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 474 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension compared with vehicle in the treatment of bacterial conjunctivitis. This study was conducted as a phase IIb study and continued with further enrollment as a phase III study.
Conditions Studied
Interventions
- DRUG Besifloxacin
- DRUG Vehicle (Placebo)
Study Locations (1)
New York
- Bausch & Lomb Incorporated - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 474 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00972777
The ClinicalTrials.gov registry entry for NCT00972777 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 474 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 557-participant average among 7 other Bacterial Conjunctivitis trials with a reported enrollment target (15% lower). The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bacterial Conjunctivitis appearing as the primary indexed condition, and to 2 interventions - of which Besifloxacin is the first listed.
NCT00972777 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00972777 about?
NCT00972777 is a clinical study titled "Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis". This study is being conducted to evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension compared with vehicle in the treatment of bacterial conjunctivitis. This study was conducted as a phase IIb study and continued with further enrollment as a phase III study.
What is the current status of trial NCT00972777?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 474 participants. The study started on 2009-10. Estimated completion is 2011-02.
What conditions does trial NCT00972777 study?
This clinical trial studies the following conditions: Bacterial Conjunctivitis.
What interventions are being tested in trial NCT00972777?
The interventions under investigation include: Besifloxacin (DRUG), Vehicle (Placebo) (DRUG).
Who is sponsoring clinical trial NCT00972777?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00972777 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bacterial Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
RECRUITING · Phase 3
-
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
COMPLETED · Phase 3
-
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)
COMPLETED · Phase 3
-
AL-15469A for the Treatment of Bacterial Conjunctivitis
COMPLETED · Phase 3
-
Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment
COMPLETED · Phase 4
-
AL-15469A for the Treatment of Bacterial Conjunctivitis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.